HU177031B - Sposob poluchenija novykh 2-/4-khinolinil-amino/-5-ftoro-benzojnoj kisloty - Google Patents
Sposob poluchenija novykh 2-/4-khinolinil-amino/-5-ftoro-benzojnoj kisloty Download PDFInfo
- Publication number
- HU177031B HU177031B HU78RO1003A HURO001003A HU177031B HU 177031 B HU177031 B HU 177031B HU 78RO1003 A HU78RO1003 A HU 78RO1003A HU RO001003 A HURO001003 A HU RO001003A HU 177031 B HU177031 B HU 177031B
- Authority
- HU
- Hungary
- Prior art keywords
- acid
- formula
- quinolinylamino
- trifluoromethyl
- product
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
- 238000002360 preparation method Methods 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 30
- 239000002253 acid Substances 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 18
- -1 phenyl-piperazin-1-yl Chemical group 0.000 claims description 17
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 12
- 239000011707 mineral Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- NBHKDVFSWLHYJR-UHFFFAOYSA-N 5-fluoro-2-(quinolin-4-ylamino)benzoic acid Chemical class OC(=O)C1=CC(F)=CC=C1NC1=CC=NC2=CC=CC=C12 NBHKDVFSWLHYJR-UHFFFAOYSA-N 0.000 claims description 5
- 230000000202 analgesic effect Effects 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 230000003301 hydrolyzing effect Effects 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 238000005809 transesterification reaction Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 150000005653 4-chloroquinolines Chemical class 0.000 claims description 2
- FPQMGQZTBWIHDN-UHFFFAOYSA-N 5-fluoroanthranilic acid Chemical compound NC1=CC=C(F)C=C1C(O)=O FPQMGQZTBWIHDN-UHFFFAOYSA-N 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000047 product Substances 0.000 description 57
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
- 239000000243 solution Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000013078 crystal Substances 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000010992 reflux Methods 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 208000025865 Ulcer Diseases 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000004494 ethyl ester group Chemical group 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000007891 compressed tablet Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- UAJCXPLDRIQWRP-UHFFFAOYSA-N 2-[(7-chloroquinolin-4-yl)amino]-5-fluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 UAJCXPLDRIQWRP-UHFFFAOYSA-N 0.000 description 3
- MSZAAINDDMYZQK-UHFFFAOYSA-N 2-amino-5-fluoro-3-methylbenzoic acid Chemical compound CC1=CC(F)=CC(C(O)=O)=C1N MSZAAINDDMYZQK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- FRLHRTUBWUUAFG-UHFFFAOYSA-N methyl 5-fluoro-2-[[8-(trifluoromethyl)quinolin-4-yl]amino]benzoate Chemical compound COC(=O)C1=CC(F)=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 FRLHRTUBWUUAFG-UHFFFAOYSA-N 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- XLEJHSGYBLEMCI-UHFFFAOYSA-N 2,3-dihydroxypropyl 5-fluoro-2-[[8-(trifluoromethyl)quinolin-4-yl]amino]benzoate Chemical compound OCC(O)COC(=O)C1=CC(F)=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 XLEJHSGYBLEMCI-UHFFFAOYSA-N 0.000 description 2
- HXEWMTXDBOQQKO-UHFFFAOYSA-N 4,7-dichloroquinoline Chemical compound ClC1=CC=NC2=CC(Cl)=CC=C21 HXEWMTXDBOQQKO-UHFFFAOYSA-N 0.000 description 2
- HQYCQIWWCBOKKI-UHFFFAOYSA-N 5-fluoro-2-[[7-(trifluoromethyl)quinolin-4-yl]amino]benzoic acid Chemical compound FC(C1=CC=C2C(=CC=NC2=C1)NC1=C(C(=O)O)C=C(C=C1)F)(F)F HQYCQIWWCBOKKI-UHFFFAOYSA-N 0.000 description 2
- JBAFPLJQMLMGAH-UHFFFAOYSA-N 5-fluoro-2-[[8-(trifluoromethyl)quinolin-4-yl]amino]benzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 JBAFPLJQMLMGAH-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000010425 asbestos Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 229960002887 deanol Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LYEAUCRITXBJTG-UHFFFAOYSA-N methyl 2-[(7-chloroquinolin-4-yl)amino]-5-fluorobenzoate Chemical compound COC(=O)C1=CC(F)=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 LYEAUCRITXBJTG-UHFFFAOYSA-N 0.000 description 2
- WGRQWIFSBUXXBX-UHFFFAOYSA-N methyl 5-fluoro-2-[[7-(trifluoromethyl)quinolin-4-yl]amino]benzoate Chemical compound COC(=O)C1=CC(F)=CC=C1NC1=CC=NC2=CC(C(F)(F)F)=CC=C12 WGRQWIFSBUXXBX-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910052895 riebeckite Inorganic materials 0.000 description 2
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QWZCWFGMJGJBLE-UHFFFAOYSA-N 2,3-dihydroxypropyl 5-fluoro-2-[[7-(trifluoromethyl)quinolin-4-yl]amino]benzoate Chemical compound OCC(O)COC(=O)C1=CC(F)=CC=C1NC1=CC=NC2=CC(C(F)(F)F)=CC=C12 QWZCWFGMJGJBLE-UHFFFAOYSA-N 0.000 description 1
- NPHULPIAPWNOOH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(2,3-dihydroindol-1-ylmethyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCC2=CC=CC=C12 NPHULPIAPWNOOH-UHFFFAOYSA-N 0.000 description 1
- GQTIMPLUHKAFLZ-UHFFFAOYSA-N 2-chloro-8-(trifluoromethyl)quinoline Chemical compound C1=C(Cl)N=C2C(C(F)(F)F)=CC=CC2=C1 GQTIMPLUHKAFLZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LLRQVSZVVAKRJA-UHFFFAOYSA-N 4-chloro-7-(trifluoromethyl)quinoline Chemical compound ClC1=CC=NC2=CC(C(F)(F)F)=CC=C21 LLRQVSZVVAKRJA-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- XQKRYBXCYCKQLL-UHFFFAOYSA-N dimethylaminomethanol Chemical compound CN(C)CO XQKRYBXCYCKQLL-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- IYWCBYFJFZCCGV-UHFFFAOYSA-N formamide;hydrate Chemical compound O.NC=O IYWCBYFJFZCCGV-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- QVDHDLGBWADBND-UHFFFAOYSA-N methyl 2-[(8-chloroquinolin-4-yl)amino]-5-fluorobenzoate Chemical compound COC(=O)C1=CC(F)=CC=C1NC1=CC=NC2=C(Cl)C=CC=C12 QVDHDLGBWADBND-UHFFFAOYSA-N 0.000 description 1
- PUDDYSBKCDKATP-UHFFFAOYSA-N methyl 2-amino-5-fluorobenzoate Chemical compound COC(=O)C1=CC(F)=CC=C1N PUDDYSBKCDKATP-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7737835A FR2411832A1 (fr) | 1977-12-15 | 1977-12-15 | Nouveaux derives de l'acide 2/(4-quinoleinyl) amino/5-fluorobenzoique, leur procede de preparation et leur application comme medicament. |
| FR7737836A FR2411833A1 (fr) | 1977-12-15 | 1977-12-15 | Nouveaux derives de l'acide 2(/4-quinoleinyl/amino) 5-fluoro benzoique, leur procede de preparation et leur application comme medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HU177031B true HU177031B (hu) | 1981-06-28 |
Family
ID=26220343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU78RO1003A HU177031B (hu) | 1977-12-15 | 1978-12-14 | Sposob poluchenija novykh 2-/4-khinolinil-amino/-5-ftoro-benzojnoj kisloty |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US4233305A (en, 2012) |
| JP (1) | JPS5488277A (en, 2012) |
| AR (1) | AR224116A1 (en, 2012) |
| AT (1) | AT365578B (en, 2012) |
| AU (1) | AU520983B2 (en, 2012) |
| CA (1) | CA1115276A (en, 2012) |
| CH (1) | CH636350A5 (en, 2012) |
| DE (1) | DE2854341A1 (en, 2012) |
| DK (1) | DK149845C (en, 2012) |
| ES (1) | ES475686A1 (en, 2012) |
| FI (1) | FI70574C (en, 2012) |
| GB (1) | GB2010243B (en, 2012) |
| HU (1) | HU177031B (en, 2012) |
| IE (1) | IE47618B1 (en, 2012) |
| IL (1) | IL56156A (en, 2012) |
| IT (1) | IT1107671B (en, 2012) |
| LU (1) | LU80660A1 (en, 2012) |
| NL (1) | NL7812206A (en, 2012) |
| PT (1) | PT68916A (en, 2012) |
| SE (1) | SE448091B (en, 2012) |
| SU (1) | SU837322A3 (en, 2012) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6322584A (ja) * | 1986-07-15 | 1988-01-30 | Senjiyu Seiyaku Kk | １−ハイドロキシ−５−オキソ−５Ｈ−ピリド〔３，２−ａ〕フエノキサジン−３−カルボン酸エステル類 |
| IL89029A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| IS4164A (is) * | 1993-06-11 | 1994-12-12 | Ab Astra | Efnasambönd sem hindra flæði magasýru |
| US5578607A (en) * | 1993-12-17 | 1996-11-26 | The Procter & Gamble Company | 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3232944A (en) * | 1966-02-01 | Monoglycerides 0f (carbgxy pl-ienyl amtno) chlgroqukngltnes | ||
| CH408915A (fr) * | 1962-02-16 | 1966-03-15 | Roussel Uclaf | Procédé de préparation d'un nouveau composé utilisable, notamment, pour le traitement des manifestations inflammatoires et/ou douloureuses |
| CA731646A (en) * | 1962-05-08 | 1966-04-05 | Roussel-Uclaf | 4-(2'(.beta.-MORPHOLYLETHOXYCARBONYL) PHENYLAMINE) 7-CHLORO QUINOLEINE ET SES SELS, AINSI QUE LEUR PROCEDE DE PREPARATION |
| FR6935M (en, 2012) * | 1967-12-29 | 1969-05-05 | ||
| FR7870M (en, 2012) * | 1968-11-08 | 1970-04-27 | ||
| ZA726593B (en) * | 1971-10-19 | 1973-06-27 | Abbott Lab | Novel derivatives of 2,3-dihydroxypropyl-n-(7 or 8-chloro-4-quinolinyl)anthranilate |
| CH585221A5 (en, 2012) * | 1972-07-28 | 1977-02-28 | Synthelabo | |
| US3971789A (en) * | 1972-10-21 | 1976-07-27 | John Wyeth & Brother Limited | O-(4-Quinolylamino)benzamides |
| FR2233059B1 (en, 2012) * | 1973-06-13 | 1976-09-03 | Roussel Uclaf | |
| GB1474296A (en) * | 1975-01-23 | 1977-05-18 | Wyeth John & Brother Ltd | 4-aminoquinoline derivatives |
-
1978
- 1978-11-16 SE SE7811839A patent/SE448091B/sv not_active IP Right Cessation
- 1978-12-04 ES ES475686A patent/ES475686A1/es not_active Expired
- 1978-12-06 US US05/966,964 patent/US4233305A/en not_active Expired - Lifetime
- 1978-12-07 SU SU782696357A patent/SU837322A3/ru active
- 1978-12-08 IL IL56156A patent/IL56156A/xx unknown
- 1978-12-13 FI FI783833A patent/FI70574C/fi not_active IP Right Cessation
- 1978-12-14 DK DK561278A patent/DK149845C/da not_active IP Right Cessation
- 1978-12-14 HU HU78RO1003A patent/HU177031B/hu not_active IP Right Cessation
- 1978-12-14 PT PT68916A patent/PT68916A/pt unknown
- 1978-12-14 JP JP15380478A patent/JPS5488277A/ja active Granted
- 1978-12-14 LU LU80660A patent/LU80660A1/xx unknown
- 1978-12-14 IE IE2476/78A patent/IE47618B1/en unknown
- 1978-12-14 AU AU42528/78A patent/AU520983B2/en not_active Expired
- 1978-12-14 GB GB7848546A patent/GB2010243B/en not_active Expired
- 1978-12-14 AR AR274807A patent/AR224116A1/es active
- 1978-12-14 IT IT52296/78A patent/IT1107671B/it active
- 1978-12-14 CA CA317,952A patent/CA1115276A/fr not_active Expired
- 1978-12-15 AT AT0897378A patent/AT365578B/de not_active IP Right Cessation
- 1978-12-15 CH CH1279478A patent/CH636350A5/fr not_active IP Right Cessation
- 1978-12-15 DE DE19782854341 patent/DE2854341A1/de active Granted
- 1978-12-15 NL NL7812206A patent/NL7812206A/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AT365578B (de) | 1982-01-25 |
| SE448091B (sv) | 1987-01-19 |
| DK561278A (da) | 1979-06-16 |
| CA1115276A (fr) | 1981-12-29 |
| DK149845B (da) | 1986-10-13 |
| ES475686A1 (es) | 1979-04-16 |
| FI70574C (fi) | 1986-09-24 |
| SE7811839L (sv) | 1979-06-16 |
| SU837322A3 (ru) | 1981-06-07 |
| AR224116A1 (es) | 1981-10-30 |
| DE2854341C2 (en, 2012) | 1990-05-23 |
| GB2010243A (en) | 1979-06-27 |
| LU80660A1 (fr) | 1979-07-20 |
| GB2010243B (en) | 1982-05-19 |
| US4233305A (en) | 1980-11-11 |
| JPS5488277A (en) | 1979-07-13 |
| FI70574B (fi) | 1986-06-06 |
| DK149845C (da) | 1987-03-02 |
| IE47618B1 (en) | 1984-05-02 |
| NL7812206A (nl) | 1979-06-19 |
| AU520983B2 (en) | 1982-03-11 |
| IL56156A0 (en) | 1979-03-12 |
| IT7852296A0 (it) | 1978-12-14 |
| DE2854341A1 (de) | 1979-06-28 |
| AU4252878A (en) | 1979-06-21 |
| IE782476L (en) | 1979-06-15 |
| JPS631305B2 (en, 2012) | 1988-01-12 |
| ATA897378A (de) | 1981-06-15 |
| CH636350A5 (fr) | 1983-05-31 |
| PT68916A (fr) | 1979-01-01 |
| IL56156A (en) | 1984-11-30 |
| FI783833A7 (fi) | 1979-06-16 |
| IT1107671B (it) | 1985-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2705446C2 (en, 2012) | ||
| US4226878A (en) | Imidazole derivative | |
| US4277497A (en) | Analgesic 2-(M-benzoylphenoxy)-propionic acid derivatives | |
| US4882349A (en) | Pyrrolacetic amides having antiinflammatory activity | |
| GB2054588A (en) | Amino-ether oxides and pharmaceutical formulations thereof | |
| JPH0347162A (ja) | 医薬品として有用な１個またはそれ以上のアミノスルホニルオキシ基を有する化合物類 | |
| IE49875B1 (en) | Derivatives of 3-quinoline-carboxylic acid | |
| JP3122792B2 (ja) | 新規な活性化合物 | |
| GB1576007A (en) | Hypolipidaemic compositions | |
| GB2082581A (en) | 4h-1,2,4-triazole derivatives | |
| DE4325204C2 (de) | Acylpyrrolalkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶ | |
| HU177031B (hu) | Sposob poluchenija novykh 2-/4-khinolinil-amino/-5-ftoro-benzojnoj kisloty | |
| CH648827A5 (fr) | Phenoxyamines heterocycliques substituees, leur preparation et medicaments consistant de ou comprenant ces composes. | |
| DE3320102A1 (de) | Neue, in 2-stellung substituierte derivate der 4-hydroxy-3-chinolincarbonsaeure, deren herstellung, deren verwendung als arzneimittel, die sie enthaltenden zusammensetzungen und erhaltene zwischenprodukte | |
| CA1139763A (fr) | Procede d'obtention de nouveaux aryltrifluoroethanols | |
| AU2022448086B2 (en) | Pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for s1pr1 and s1pr4 | |
| HU190543B (en) | Process for producing 5-/vynil-or 4-ethinyl-benzoyl/-1,2-dihydro-3h-pyrrolo /1,2-a/pyrrol-1-carboxylic acids and their derivatives | |
| EP0083222B1 (en) | New quinolylacetic acid compounds and pharmaceutical compositions containing them | |
| EP0041630B1 (en) | New 3h-naphtho(1,2-d)imidazoles, the process for preparing them, the compounds for use as antiinflammatory agents and compositions containing them | |
| HU202526B (en) | Process for producing new 4-oh-quinolinecarboxylic acid derivatives and pharmaceutical compositions comprising such compounds | |
| JPS6185370A (ja) | ４ｈ‐１，２，４‐トリアゾール誘導体の新製造法、得られる新トリアゾール、それらの薬剤としての使用及びそれらを含む製薬組成物 | |
| HU197327B (en) | Process for production of new esthers of derivatives of 4-hydroxi-kinolin-3-carbon substituated by carbon-chain containing in position-2 l-hydroxi group and medical preparatives containing thereof as active substance | |
| JP2008512384A (ja) | Ｐｐａｒアゴニスト活性を有するフィブラート化合物 | |
| SK278791B6 (sk) | Izochinolínové deriváty, spôsob ich výroby a farma | |
| EP0363273B1 (fr) | Dérivés 17 soufrés de la 20,21-dinoréburnaménine, leur procédé de préparation et les intermédiaires ainsi obtenus, leur application comme médicaments et les compositions pharmaceutiques les renfermant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HU90 | Patent valid on 900628 | ||
| HMM4 | Cancellation of final prot. due to non-payment of fee |